Related Experiment Video

Updated: Jul 15, 2026

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
08:11

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice

Published on: September 26, 2011

Metabotropic glutamate receptors: new targets for the control of tumor growth?

Ferdinando Nicoletti1, Antonietta Arcella, Luisa Iacovelli

  • 1Istituto Neurologico Mediterraneo Neuromed, Località Camerelle, Pozzilli 86079, Italy. ferdinandonicoletti@hotmail.com

Trends in Pharmacological Sciences
|April 17, 2007
PubMed

Insights

Metabotropic glutamate (mGlu) receptors regulate neural stem-progenitor cell proliferation, offering new therapeutic targets for brain tumors. Targeting specific mGlu receptor subtypes may treat malignant gliomas, medulloblastomas, and melanomas.

Area of Science:

  • Neuroscience
  • Oncology

Background:

  • Cancer stem cells are key targets for malignant tumor treatment.
  • Malignant gliomas and medulloblastomas originate from transformed neural stem-progenitor cells.
  • Neural stem-progenitor cell proliferation is regulated by metabotropic glutamate (mGlu) receptors.

Purpose of the Study:

  • To investigate the role of mGlu receptors in brain tumor development.
  • To identify specific mGlu receptor subtypes as potential therapeutic targets for brain tumors.

Main Methods:

  • The study focuses on the regulatory role of G-protein-coupled receptors, specifically mGlu receptors, in neural stem-progenitor cell proliferation.
  • Investigated the involvement of mGlu receptor subtypes in the proliferation of brain tumor cells and melanoma development.

Main Results:

  • mGlu(3) and mGlu(4) receptor subtypes regulate the proliferation of brain tumor cells.
  • mGlu(1) receptors are implicated in melanoma development.
  • Specific mGlu receptor subtypes control neural stem-progenitor cell proliferation.

Conclusions:

  • Individual mGlu receptor subtypes represent promising new therapeutic targets for various malignant tumors.
  • Targeting mGlu receptors offers a potential strategy for treating brain tumors like malignant gliomas and medulloblastomas.
  • Further research into mGlu receptor modulation could lead to novel cancer therapies.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...